BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 21371048)

  • 1. The pharmaceuticalisation of society? A framework for analysis.
    Williams SJ; Martin P; Gabe J
    Sociol Health Illn; 2011 Jul; 33(5):710-25. PubMed ID: 21371048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolving sociological analyses of 'pharmaceuticalisation': a response to Williams, Martin and Gabe.
    Abraham J
    Sociol Health Illn; 2011 Jul; 33(5):726-8; discussion 729-30. PubMed ID: 21777253
    [No Abstract]   [Full Text] [Related]  

  • 3. [An analysis of the pharmaceuticals market in Vietnam].
    Simonet D
    Sante; 2001; 11(3):155-60. PubMed ID: 11641078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are pharmaceutical marketing decisions calibrated to communications effects?
    Cavusgil E; Calantone R
    Health Mark Q; 2011 Oct; 28(4):317-36. PubMed ID: 22054028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health identities: from expert patient to resisting consumer.
    Fox N; Ward K
    Health (London); 2006 Oct; 10(4):461-79. PubMed ID: 16973681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 'Get with the Program!': pharmaceutical marketing, symptom checklists and self-diagnosis.
    Ebeling M
    Soc Sci Med; 2011 Sep; 73(6):825-32. PubMed ID: 21835526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The economics of prescription drug prices, government intervention, and the importation of drugs from Canada.
    Openshaw MS
    Nurs Econ; 2005; 23(6):307-11, 279. PubMed ID: 16459902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The sociology of pharmaceuticals: progress and prospects.
    Williams SJ; Gabe J; Davis P
    Sociol Health Illn; 2008 Sep; 30(6):813-24. PubMed ID: 18761505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharma in the bedroom . . . and the kitchen. . . . The pharmaceuticalisation of daily life.
    Fox NJ; Ward KJ
    Sociol Health Illn; 2008 Sep; 30(6):856-68. PubMed ID: 18761507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmaceutical marketing in a new age. Effective campaigns still need to focus on what customers want.
    Rao SK
    Mark Health Serv; 2002; 22(1):6-12. PubMed ID: 11881547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Converging prescription brand shares as evidence of physician learning.
    Walker D
    Health Mark Q; 2012; 29(2):163-79. PubMed ID: 22676843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risky business.
    Ment Health Today; 2005 May; ():12-3. PubMed ID: 15938578
    [No Abstract]   [Full Text] [Related]  

  • 14. The undiscovered Argentine pharmaceutical market.
    Felix PF; Thomas RK; Pol LG
    Mark Health Serv; 2001; 21(4):12-6. PubMed ID: 11763647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The interweaving of pharmaceutical and medical expectations as dynamics of micro-pharmaceuticalisation: advanced-stage cancer patients' hope in medicines alongside trust in professionals.
    Brown P; de Graaf S; Hillen M; Smets E; van Laarhoven H
    Soc Sci Med; 2015 Apr; 131():313-21. PubMed ID: 25465500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sociology of pharmaceuticals development and regulation: a realist empirical research programme.
    Abraham J
    Sociol Health Illn; 2008 Sep; 30(6):869-85. PubMed ID: 18761508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How should we support pharmaceutical innovation?
    Grootendorst P
    Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):313-20. PubMed ID: 19670991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoliberal technocracy: explaining how and why the US Food and Drug Administration has championed pharmacogenomics.
    Hogarth S
    Soc Sci Med; 2015 Apr; 131():255-62. PubMed ID: 25661300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The promise of pharmacogenetics: assessing the prospects for disease and patient stratification.
    Smart A; Martin P
    Stud Hist Philos Biol Biomed Sci; 2006 Sep; 37(3):583-601. PubMed ID: 16980196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.